New York’s Hoth Therapeutics Inc (NASDAQ: HOTH) soared on Tuesday morning after revealing that one of its therapeutics had demonstrated a 100 per cent success rate at achieving its desired outcome in a Phase 2a clinical trial.
“HT-001” has proven that it can alleviate skin issues caused by epidermal growth factor receptor inhibitors — drugs used to treat multiple cancers.
“These results are a significant milestone, underscoring HT-001’s potential to transform patient care by mitigating debilitating skin toxicities while maintaining critical cancer treatments,” chief executive Robb Knie said. He added that the strong safety profile the drug has shown indicates that it has the potential to set a new standard for treatment in an underserved area.
All of the patients in the study “achieved the primary efficacy endpoint” of an Acneiform Rash Investigator Global Assessment Scale score less than or equal to one, Hoth says. They all showed substantial skin toxicity improvements six weeks post-treatment.
“The innovative scale [developed by oncology and dermatology specialists] ensures precise measurement and assessment of skin toxicity improvements,” Hoth explained.
Furthermore, 66 per cent of the trial participants reported reduced pain and itching, affirming the drug’s efficacy.
No adverse events were reported either.
A Thai lung cancer patient developed a nasty skin condition from the epidermal growth factor receptor inhibitor drug “erlotinib” 10 days post-administration in 2015. Photo credit: Indian Journal of Dermatology, Venereology and Leprology
Read more: Breath Diagnostics onboards new president and closes critical financing
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Hoth invests in Bitcoin
The biopharmaceutical operator recently bought US$1 million worth of the popular cryptocurrency to help diversify its assets.
“We believe its inflation-resistant characteristics may make it a reliable asset as a functional store of value,” Knie said Nov. 20.
Hoth is a relatively small company with a market capitalization of US$5.66 million.
In the pipeline, it has other drugs being advanced in early-stage studies for the treatment of cancer, acne, asthma, traumatic brain injury, inflammatory bowel diseases and Alzheimer’s.
The company recently announced a collaboration with the Department of Veterans Affairs to develop an obesity treatment technology too.
rowan@mugglehead.com
